15,865 Shares in Agenus Inc. $AGEN Bought by Savant Capital LLC

Savant Capital LLC acquired a new stake in Agenus Inc. (NASDAQ:AGEN) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,865 shares of the biotechnology company’s stock, valued at approximately $73,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bank of Montreal Can purchased a new stake in shares of Agenus in the 2nd quarter valued at about $75,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Agenus in the second quarter valued at approximately $85,000. CWM LLC grew its position in shares of Agenus by 105.8% during the second quarter. CWM LLC now owns 26,246 shares of the biotechnology company’s stock worth $120,000 after acquiring an additional 13,494 shares during the last quarter. Ovata Capital Management Ltd acquired a new position in shares of Agenus in the 2nd quarter valued at $146,000. Finally, Acadian Asset Management LLC acquired a new stake in Agenus during the 1st quarter worth $58,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Trading Down 1.6%

Shares of AGEN opened at $4.22 on Friday. The stock’s 50 day moving average is $4.14 and its two-hundred day moving average is $4.55. Agenus Inc. has a twelve month low of $1.38 and a twelve month high of $7.34. The firm has a market capitalization of $143.51 million, a PE ratio of -0.59 and a beta of 1.43.

Agenus (NASDAQ:AGEN) last issued its earnings results on Monday, November 10th. The biotechnology company reported $1.94 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.63 by ($0.69). The firm had revenue of $30.24 million during the quarter, compared to analyst estimates of $80.39 million. On average, sell-side analysts predict that Agenus Inc. will post -12.55 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. HC Wainwright restated a “buy” rating on shares of Agenus in a research note on Monday, October 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agenus in a research note on Wednesday. Zacks Research upgraded Agenus to a “hold” rating in a research note on Tuesday, August 12th. Finally, Wall Street Zen cut Agenus from a “buy” rating to a “hold” rating in a research note on Sunday, August 17th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $14.50.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.